uniQure disclosed that its investigational AAV gene therapy AMT‑191 produced sustained, dose‑dependent increases in α‑galactosidase A activity in 11 patients enrolled in a Phase I/IIa trial for Fabry disease. The reported activity ranges were 0.34‑ to 82.2‑fold above normal at the lowest dose (4 × 10^13 gc/kg), 1.6‑ to 312.52‑fold at the mid dose (2 × 10^13 gc/kg), and 27.7‑ to 223.7‑fold at the highest dose (6 × 10^13 gc/kg). Durability was observed for more than a year in the high‑dose cohort, indicating a durable therapeutic effect.
The safety profile was largely reassuring, with no serious adverse events linked to AMT‑191 at any dose. Two patients receiving the 4 × 10^13 gc/kg dose experienced asymptomatic Grade 3 liver enzyme elevations, prompting a temporary pause in dosing for both the mid‑ and high‑dose cohorts. The pause was managed with corticosteroids and did not result in any long‑term liver injury, but it underscores the need for careful monitoring of hepatotoxicity as the therapy advances.
From a business perspective, the efficacy data reinforce uniQure’s position as a potential one‑time treatment for Fabry disease, a condition currently managed with lifelong enzyme replacement therapy. The sustained enzyme activity and the ability of some patients to discontinue replacement therapy suggest a meaningful clinical benefit that could translate into a differentiated product in a niche market. The pause in dosing, however, introduces a safety headwind that may delay regulatory submissions and affect investor confidence, as the company must demonstrate a favorable risk‑benefit profile before progressing to larger trials.
Chief Medical Officer Walid Abi‑Saab emphasized that “these updated preliminary data reinforce our confidence in the biological activity of AMT‑191, including sustained and dose‑dependent increases in α‑gal A activity across all dose cohorts of the treated patients.” He added that the safety signals are being closely monitored and that the company is committed to optimizing dosing strategies to mitigate hepatotoxicity while preserving efficacy.
Investors reacted cautiously to the announcement. While the robust efficacy signals were welcomed, the emergence of dose‑limiting liver enzyme elevations and the subsequent dosing pause tempered enthusiasm. Market participants weighed the potential for a transformative therapy against the regulatory and safety hurdles that could delay commercialization and impact the company’s valuation trajectory.
Looking ahead, uniQure plans to resume dosing in the mid‑ and high‑dose cohorts once safety protocols are refined. The company will use the data to support a regulatory submission for a pivotal Phase III trial and to strengthen its orphan‑drug and fast‑track designations. The next milestones will include expanded patient enrollment, long‑term safety monitoring, and the collection of efficacy endpoints that will inform the company’s regulatory strategy and potential market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.